Dilek Dogan Gurluk has been appointed General Manager of Novo Nordisk Ireland, leading the company’s strategic focus on chronic disease and obesity care.
Novo Nordisk, a leading global healthcare company renowned for its expertise in diabetes, obesity, and rare chronic diseases has appointed Dilek Dogan Gurluk as General Manager of Novo Nordisk Ireland.
Speaking about her appointment, Dilek Dogan Gurluk said: “My focus and ambition is to drive a societal shift of chronic disease management for obesity care in Ireland. I’m honoured to lead Novo Nordisk Ireland at such a pivotal time of change for our company and for healthcare more broadly. As a company we need to consistently push ourselves to be ambitious and unlock the potential this great company has. Novo Nordisk can proudly stand over a track record of innovation that has not only transformed the treatment of diabetes but also reshaped its societal recognition as a chronic disease.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
